What are Antiepileptic agent drugs?

Antiepileptic agent drugs are pharmacologic agents that share a common mechanism (typically targeting SV2A (synaptic vesicle protein 2A)). 6 are currently marketed, with 1 more in clinical development.

What are the marketed Antiepileptic agent drugs?

Marketed Antiepileptic agent drugs include Standard dose levetiracetam, Oral levetiracetam, LEV, Keppra, intravenous levetireacetam, Low dose levetiracetam.

Antiepileptic agent

6 marketed 1 in Phase 3

This page covers all Antiepileptic agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting SV2A (synaptic vesicle protein 2A), SV2A (synaptic vesicle glycoprotein 2A), Synaptic vesicle protein SV2A.

Targets

SV2A (synaptic vesicle protein 2A) · SV2A (synaptic vesicle glycoprotein 2A) · Synaptic vesicle protein SV2A

Marketed (6)

Standard dose levetiracetam · Mario Negri Institute for Pharmacological Research · Neurology
Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.
Oral levetiracetam · Children's Hospital of Fudan University · Neurology
Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.
LEV · GlaxoSmithKline · Neurology
LEV (levetiracetam) reduces neuronal excitability and seizure propagation through binding to synaptic vesicle protein SV2A.
Keppra · Generic (originally UCB Pharma) · Metabolic
Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis.
intravenous levetireacetam · ayesha tariq · Neurology
Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.
Low dose levetiracetam · Richard H. Haas · Neurology
Low-dose levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.

Phase 3 pipeline (1)

Lévétiracetam · Hospices Civils de Lyon · Neurology
Levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, thereby modulating neurotransmitter release and preventing seizure propagation.